High throughput genome-wide translocation sequencing

Patent metadata

Field	Value
Publication number	US-9518293-B2
Application number	US-201214131236-A
Country	US
Kind code	B2
Filing date	Jul 6, 2012
Priority date	Jul 7, 2011
Publication date	Dec 13, 2016
Grant date	Dec 13, 2016

Abstract

Provided are methods for high-throughput screening to determine locations of double-stranded DNA breaks (DSBs) and translocations in genomes caused by different agents, such as enzymes.

First claim

We claim:

1. A method for high throughput, genome-wide translocation sequencing (HTGTS) and detection of double-stranded DNA break (DSB) locations, the method comprising the steps of:
a. exposing a cell to an agent known or suspected of being capable of producing at least one DSB;
b. optionally allowing the cell to divide for at least 12 hours;
c. extracting genomic DNA from the cells;
d. producing a fragmented DNA sample by fragmenting the DNA of the cell with a frequently cutting restriction enzyme;
e. producing a ligated DNA product by ligating an asymmetric adapter to the fragmented DNA sample, wherein the asymmetric adapter comprises a sequence that is designed to anneal to the DNA end generated by the frequently cutting restriction enzyme and contains a stretch of known DNA sequence that can be used to design a PCR primer for a nested PCR amplification;
f. digesting the ligated DNA products with an enzyme to block amplification of germline or unrearranged targeted alleles;
g. producing nested PCR products by performing nested-PCR with adapter- and locus-specific primers using the digested ligated DNA product thereby amplifying the nucleic acid sequences surrounding the junctions around the DSBs;
h. producing sequenced nested PCR products by sequencing the nested PCR products; and
i. aligning the sequenced nested PCR products against a reference sequence to identify chromosomal locations of the translocations and the chromosomal locations of the DSBs.

2. The method of claim 1 , further comprising a step of inserting into a cell to be analyzed at least one target sequence for the agent that is known to be absent in the genome of the cell to be analyzed prior to step (a) of claim 1 .

3. The method of claim 2 , wherein the agent is a rare-cutting enzyme.

4. The method of claim 1 , wherein the agent is a meganuclease, a transcription activator-like effector nuclease which are sequence specific nucleases made by fusing a transcription activator like effector DNA-binding domain to a catalytic domain of an endonuclease or a zinc-finger nuclease.

5. The method of claim 1 , wherein the cells are allowed to divide for 1-5 days.

6. The method of claim 1 , wherein the cells are allowed to divide for 2-4 days.

7. The method of claim 1 , wherein the step of aligining is performed by a non-human machine.

8. The method of claim 7 , wherein the non-human machine comprises a computer executable software.

9. The method of claim 8 further comprising a display module for displaying the results of the step of aligning.

10. The method of claim 1 , wherein the cell is a mammalian cell.

11. The method of claim 1 , wherein the cell is a plant cell.

Assignees

• Alt Frederick W
• Yu Zhang
• Chiarle Roberto
• Gostissa Monica
• Children'S Medical Center Corp

Inventors

• Alt Frederick W
• Yu Zhang
• Chiarle Roberto
• Gostissa Monica

Classifications

• C12Q1/6855

  Ligating adaptors · CPC title

• G16B30/00

  ICT specially adapted for sequence analysis involving nucleotides or amino acids · CPC title

• C12Q1/6874 Primary

  involving nucleic acid arrays, e.g. sequencing by hybridisation · CPC title

• C12Q1/6869 Primary

  Methods for sequencing · CPC title

• C12Q2549/119

  using nested primers · CPC title